Relevant bibliographies by topics / Breast disease; Cancer

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Breast disease; Cancer'

Author: Grafiati
Published: 4 June 2021
Last updated: 10 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Breast disease; Cancer.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Breast disease; Cancer"

1

Wolden, Suzanne L., Steven L. Hancock, Robert W. Carlson, Don R. Goffinet, Stefanie S. Jeffrey, and Richard T. Hoppe. "Management of Breast Cancer After Hodgkin’s Disease." Journal of Clinical Oncology 18, no. 4 (February 14, 2000): 765. http://dx.doi.org/10.1200/jco.2000.18.4.765.

Full text
Abstract:
PURPOSE: To evaluate the incidence, detection, pathology, management, and prognosis of breast cancer occurring after Hodgkin’s disease. PATIENTS AND METHODS: Seventy-one cases of breast cancer in 65 survivors of Hodgkin’s disease were analyzed. RESULTS: The median age at diagnosis was 24.6 years for Hodgkin’s disease and 42.6 years for breast cancer. The relative risk for invasive breast cancer after Hodgkin’s disease was 4.7 (95% confidence interval, 3.4 to 6.0) compared with an age-matched cohort. Cancers were detected by self-examination (63%), mammography (30%), and physician exam (7%). The histologic distribution paralleled that reported in the general population (85% ductal histology) as did other features (27% positive axillary lymph nodes, 63% positive estrogen receptors, and 25% family history). Although 87% of tumors were less than 4 cm, 95% were managed with mastectomy because of prior radiation. Two women underwent lumpectomy with breast irradiation. One of these patients developed tissue necrosis in the region of overlap with the prior mantle field. The incidence of bilateral breast cancer was 10%. Adjuvant systemic therapy was well tolerated; doxorubicin was used infrequently. Ten-year disease-specific survival was as follows: in-situ disease, 100%; stage I, 88%; stage II, 55%; stage III, 60%; and stage IV, zero. CONCLUSION: The risk of breast cancer is increased after Hodgkin’s disease. Screening has been successful in detecting early-stage cancers. Pathologic features and prognosis are similar to that reported in the general population. Repeat irradiation of the breast can lead to tissue necrosis, and thus, mastectomy remains the standard of care in most cases.
APA, Harvard, Vancouver, ISO, and other styles
2

Karlin, N. J., I. Chopra, J. Mirocha, and N. Feldman. "An association between thyroid disease and breast cancer." Journal of Clinical Oncology 25, no. 18_suppl (June 20, 2007): 21063. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.21063.

Full text
Abstract:
21063 Background: Anecdotal studies and isolated case reports have observed an association of thyroid disease and breast cancer. This purported association remains controversial. We describe a retrospective case-control study on the prevalence of breast cancer in patients with abnormal thyroid function studies. Age-matched subjects served as controls. Methods: We reviewed 6211 cases of abnormal TSH values between 1/04 and 12/05 and determined the number of cases with breast cancer. We compared those data to 3,151 control subjects with normal TSH seen during the same period. We excluded patients with thyroid cancer from the total number of malignancies in both groups because abnormal TSH would be expected to result from its treatment. We also reviewed the ER, PR, her 2 neu status and free thyroxine of patients with breast cancers. Results: Breast cancer rate of 36% of all cancers (37/102) in the abnormal TSH group was significantly higher than that of 18% (14/77) in the normal TSH group. (p = 0.012). Breast cancers in the study group with abnormal thyroid function were more frequently hormone receptor positive (74% vs. 67%) and her 2 neu negative (67% vs. 50%). Conclusions: The data suggest that there is an increased rate of breast cancer in patients with abnormal thyroid function. The trend of hormone receptor positive disease in the abnormal TSH group suggests that the IGF receptor may play an important role in the relationship between thyroid disease and breast cancer. The IGF receptor may be a potential target for therapeutic drug development for breast cancer prevention and management. Further studies are warranted. No significant financial relationships to disclose.
APA, Harvard, Vancouver, ISO, and other styles
3

Soni Ahirrao, Vinanti Bhoeer, Shivani Patil, and Himani Jawale. "Breast Cancer Detection." International Journal of Engineering and Management Research 10, no. 6 (December 16, 2020): 57–60. http://dx.doi.org/10.31033/ijemr.10.6.8.

Full text
Abstract:
Breast Cancer is highly predominant in women in today’s world. It starts in the breast during the initial stages and spreads to other areas of the body after some period of time. Breast cancer is the second-largest disease leading to the death of women. The disease is curable if detected early enough. Breast Cancer Application monitors the abnormal growth of breast cells during the early stages. They are often diagnosed during the advanced stages of breast cancer. It is the second most diagnosed cancer in women, affecting one in every eight women. Our project comprises two modules, first consists of an application with user login and self-test examine section where and the second section consists of identifying benign and malignant cells. The second section will be used by doctors' side for the detection of abnormalities of breasts as early as possible by providing the user screening data set. It contains Machine Learning techniques for the classification of malignant and benign tumors. There are more treatment options and a better chance of survival. If breast cancer is detected during the early stages then there is a 93 percent of higher survival rate in the first five years.
APA, Harvard, Vancouver, ISO, and other styles
4

Chan, D. W., R. A. Beveridge, D. J. Bruzek, D. J. Damron, K. R. Bray, P. K. Gaur, D. S. Ettinger, and R. C. Rock. "Monitoring breast cancer with CA 549." Clinical Chemistry 34, no. 10 (October 1, 1988): 2000–2004. http://dx.doi.org/10.1093/clinchem/34.10.2000.

Full text
Abstract:
Abstract CA 549, a new marker for breast cancer, was measured in serum of 719 patients by an immunoradiometric assay involving two monoclonal antibodies: BC4E 549, developed against a breast-tumor cell line, and BC4N 154, developed against milk fat-globule membrane. The reference interval for healthy women was 0-11 kilo-units/L. The percentages of patients with CA 549 greater than 11 kilo-units/L for benign conditions are: 0% pregnancy, 1% breast, 26% liver; and for nonbreast metastatic cancers: 12% endometrial, 33% lung, 40% prostatic, and 50% ovarian. In women with breast cancer who were receiving or had completed adjuvant therapy with no evidence of disease there was an 11% increase in CA 549. For patients with metastatic breast cancer, 19% of those in complete remission, 63% of those in partial remission, and 88% of those with systemic progression had increased CA 549. CA 549 is a more specific marker than carcinoembryonic antigen (CEA) in nonmalignant disease, nonbreast malignancies, and adjuvant breast-cancer patients, and it is more sensitive in breast-cancer patients with progressive disease than is CEA. We could show CA 549 to be superior to CEA for detecting active breast cancer in patients with malignant or nonmalignant breast diseases. In monitoring 19 adjuvant-treated patients, CA 549 correlated more closely with the clinical course than did CEA values and, when increased, predicted a clinical recurrence. In 18 breast-cancer patients with metastasis, monitored for two to three years, the change of CA 549 values paralleled disease courses more often than did CEA values.
APA, Harvard, Vancouver, ISO, and other styles
5

Marinko, Tanja. "Pericardial disease after breast cancer radiotherapy." Radiology and Oncology 53, no. 1 (September 6, 2018): 1–5. http://dx.doi.org/10.2478/raon-2018-0035.

Full text
Abstract:
AbstractBackgroundBreast cancer is the second most common cancer worldwide. Thanks to the modern oncological treatments, disease specific survival has improved throughout the last decades. The number of breast cancer survivors has been increasing, and more and more attention has been paid to the breast cancer treatment side effects. Whereas there are many data regarding ischemic heart disease after radiotherapy for breast cancer, there is not much data in the literature about the incidence and clinical meaning of pericardial disease after breast cancer radiotherapy.ConclusionsAlthough radiation-induced pericarditis is the earliest form of radiation-induced cardiovascular disease after irradiation of the heart, it seems that in clinical practice, especially by using modern radiotherapy treatment techniques, it is underdiagnosed because patients are mostly asymptomatic. In some cases, especially in its late form and after multimodal systemic oncological treatment in combination with radiotherapy, it could be presented in severe form and life threatening. Treatment modalities for radiation-induced pericardial diseases are the same as in the non-irradiated population, but in the irradiated patients, surgery may be difficult.
APA, Harvard, Vancouver, ISO, and other styles
6

Siregar, Ice Ratnalela. "THE DESCRIPTION OF HISTOPATHOLOGY IN BREAST CANCER PATIENTS AT RSUP.H. ADAM MALIK MEDAN." Jurnal Ilmiah PANNMED (Pharmacist, Analyst, Nurse, Nutrition, Midwivery, Environment, Dentist) 13, no. 1 (January 24, 2019): 20–23. http://dx.doi.org/10.36911/pannmed.v13i1.141.

Full text
Abstract:
Breasts are an important organ for women. Breasts can experience various disorders or diseases, bothserious and mild disease. Among these are breast cancer which is one of the most dreaded breastabnormalities. Breast cancer is a cancer that comes from the gland, glandular, and breast supporttissue.Breast cancer has been known to attack only women. In fact, malignant tumors are also biased alsoagainst men. The histopathologic feature is a diagnostic feature of breast cancer. The purpose of this studywas to determine the histopathologic description of Breast Cancer at RSUP.H.Adam Malik. The sample inthis study is all breast cancer patients who have been diagnosed by doctors who visit the RSUP.H.AdamMalik (Population). The research method used is descriptive of taking secondary data in medical record atRSU.H.Adam Malik. The results of this study can be seen that of 60 breast cancer patients who do biopsy,the majority of patients have histopathology of breast cancer invasive Ductal Carcinoma as much as 31people (51.66%) and Invasive Breast Cancer Nos Type of 29 people (48.34%).
APA, Harvard, Vancouver, ISO, and other styles
7

Bernatsky, S., R. Ramsey-Goldman, M. Petri, M. B. Urowitz, D. D. Gladman, P. F. Fortin, E. Ginzler, et al. "Breast cancer in systemic lupus." Lupus 26, no. 3 (September 30, 2016): 311–15. http://dx.doi.org/10.1177/0961203316664595.

Full text
Abstract:
Objective There is a decreased breast cancer risk in systemic lupus erythematosus (SLE) versus the general population. We assessed a large sample of SLE patients, evaluating demographic and clinical characteristics and breast cancer risk. Methods We performed case-cohort analyses within a multi-center international SLE sample. We calculated the breast cancer hazard ratio (HR) in female SLE patients, relative to demographics, reproductive history, family history of breast cancer, and time-dependent measures of anti-dsDNA positivity, cumulative disease activity, and drugs, adjusted for SLE duration. Results There were 86 SLE breast cancers and 4498 female SLE cancer-free controls. Patients were followed on average for 7.6 years. Versus controls, SLE breast cancer cases tended to be white and older. Breast cancer cases were similar to controls regarding anti-dsDNA positivity, disease activity, and most drug exposures over time. In univariate and multivariate models, the principal factor associated with breast cancers was older age at cohort entry. Conclusions There was little evidence that breast cancer risk in this SLE sample was strongly driven by any of the clinical factors that we studied. Further search for factors that determine the lower risk of breast cancer in SLE may be warranted.
APA, Harvard, Vancouver, ISO, and other styles
8

Schnitt, Stuart J. "Benign Breast Disease and Breast Cancer Risk." American Journal of Surgical Pathology 27, no. 6 (June 2003): 836–41. http://dx.doi.org/10.1097/00000478-200306000-00017.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Chirappapha, Prakasit, Thongchai Sukarayothin, Yodying Wasuthit, Ronnarat Suvikapalornkul, Panuwat Lertsithichai, and Youwanush Kongdan. "Disease-free Probability and Triple-Negative Breast Cancer." Ramathibodi Medical Journal 35, no. 1 (March 30, 2012): 5–13. http://dx.doi.org/10.33165/rmj.2012.35.1.117663.

Full text
Abstract:
Objective: To compare the probabilities of local recurrence and distant metastasis between women with triple-negative and non- triple negative breast cancers. Methods: Medical and pathological records of breast cancer patients treated between the years 2002 and 2006 were reviewed. Results: There were 256 patients with complete data on estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2) expression determinations. There were 54 patients (21%) with triple-negative (ER-, PR-, HER2 -) cancers. Triple-negative patients were more likely to have larger tumors with higher histologic grade. The median fallow-up time was 4 years. The probabilities of local and distant recurrence were similar between the two groups of patients. Only two factors were independently and significantly associated with overall recurrence: tumor stage and tumor size. Conclusion: Triple-negative breast cancer did not have a higher risk for both local recurrence and distant metastasis when compared with non-triple negative cancer.
APA, Harvard, Vancouver, ISO, and other styles
10

Yu, J., E. Morris, A. Park, H. Cody, and M. L. Gemignani. "Efficacy of breast MRI in elderly women." Journal of Clinical Oncology 25, no. 18_suppl (June 20, 2007): 608. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.608.

Full text
Abstract:
608 Background: Breast MRI is useful in evaluating extent of disease and screening of high risk patients, especially younger patients with dense breasts. The utility of MRI in the elderly population is currently unknown. The purpose of this study was to review the use of breast MRI and MRI findings in elderly women. Methods: Retrospective review identified women over the age of 70 who underwent breast MRI at our institution between 11/2000 and 12/2005. Clinicopathologic features, MRI results and mammograms (MMG) were reviewed. Results: 228 patients were identified. The mean age was 73.5 years (range 70–91). Forty-three patients (19%) had no history of breast cancer, 99 (43%) had a history of breast cancer, and 86 (38%) had a current diagnosis of breast cancer at the time of MRI. Ninety-two patients (40%) underwent MRI for screening, 49 (21%) as further workup for an abnormal MMG or physical finding, and 78 (34%) for extent of disease assessment. MRI found 49 additional sites of abnormality and 15 additional cancers (14% false positive). Five cancers were detected in women with no current diagnosis of cancer. In patients with a diagnosis of cancer at the time of MRI, 10 additional cancers were found: 7 in the contralateral breast and 3 additional ipsilateral sites. Conclusions: MRI detected an additional 15 mammographically occult breast cancers in this population of women over the age of 70. MRI was efficacious in screening as well as evaluating extent of disease, with a relatively low false-positive rate of 14%. Breast MRI is a useful tool in the evaluation of elderly patients; further study in the use of MRI for screening in this population is needed. [Table: see text] No significant financial relationships to disclose.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Breast disease; Cancer"

1

Sousa, Cristovao. "Huntington disease and breast cancer." Thesis, Paris 11, 2013. http://www.theses.fr/2013PA114823/document.

Full text
Abstract:
La maladie de Huntington (MH) est une maladie neurodégénérative autosomale dominante causée par une expansion anormale de CAG dans le gène codant la huntingtine (HTT) qui se traduit dans la protéine HTT par une répétition de polyglutamine, entrainant la mort neuronale. Néanmoins, la MH entraine aussi le développement de symptômes périphériques comme la HTT est une protéine exprimée de façon ubiquitaire. Notamment, la MH a été associé à une plus faible incidence des cancers, mais les mécanismes sous-jacents ne sont pas décrits. Nous avons étudié le rôle de HTT mutée et sauvage dans le cancer du sein, où la protéine est fortement exprimée. Des modèles murins de cancer du sein (MMTV-PyVT et MMTV-ErbB2) exprimant la HTT mutée (souris knock-in transportant 111 GAC) développent des tumeurs mammaires agressives par rapport aux souris exprimant la HTT sauvage. La transition épithéliale-mésenchymateuse est accélérée avec une augmentation de la motilité cellulaire ainsi que de la formation de métastases. Ces tumeurs accumulent le récepteur tyrosine-kinase HER2 à la membrane, en raison d'un défaut d'endocytose dynamine-dépendante en présence de la HTT mutée. La signalisation accrue de HER2 est responsable de l'agressivité des tumeurs exprimant la HTT mutée, comme en témoigne le traitement trastuzumab, un anticorps dirigé contre HER2 qui restaure la motilité et l'invasion des cellules tumorales porteuses de la mutation responsable de la MH. La HTT sauvage a elle-même un rôle protecteur dans le cancer, retardant l’apparition des métastases en raison d'un potentiel rôle dans l’adhésion intercellulaire. Ainsi, notre travail met en évidence des rôles clés de la HTT mutée et sauvage au cours de la progression du cancer du sein
Huntington disease (HD) is an autosomal dominant neurodegenerative disorder caused by an abnormal CAG expansion in the huntingtin (HTT) gene. The corresponding polyglutamine expansion in the HTT protein causes specific neuronal death, but the consequences of HTT mutation in other tissues are less well understood. Nevertheless, HD mutation causes peripheral symptoms as HTT is an ubiquitous protein. HD was associated to lower cancer incidence, however, the mechanisms behind this effect were not described. Here we have studied the role of wild-type and mutant HTT in breast cancer, where we found the protein to be highly expressed. We demonstrate that mouse breast cancer models (MMTV-PyVT and MMTV-ErbB2) expressing mutant HTT (knock-in mice carrying 111 CAGs) develop aggressive mammary tumors as compared to control mice. Epithelial-to-mesenchymal transition is enhanced with subsequent increased cell motility and metastasis. These tumors accumulate tyrosine-kinase receptor HER2 at the membrane, due to a dynamin-dependent endocytosis defect in the presence of mutant HTT. HER2 enhanced signaling is responsible for the aggressiveness of the mutant HTT expressing tumors, as demonstrated by Trastuzumab treatment, an antibody against HER2 that restores motility and invasion in tumor cells carrying HD mutation. The wild-type HTT has itself a protective role in cancer, inhibiting metastasis due to a possible role in cellular junction maintenance. Thus, our work unravels a key role of HTT in breast cancer progression, with the mutant HTT triggering the development of aggressive and metastatic tumors
APA, Harvard, Vancouver, ISO, and other styles
2

Taylor, Carolyn W. "Breast cancer radiotherapy and heart disease." Thesis, University of Oxford, 2008. http://ora.ox.ac.uk/objects/uuid:c9dda3ca-8cb3-4a38-938d-0b75b4f6471d.

Full text
Abstract:
Introduction: Some past breast cancer radiotherapy regimens led to an increased risk of death from heart disease. Although heart dose from breast cancer radiotherapy has generally reduced over the past few decades, there may still be some cardiac risk. Estimation of future risk for women irradiated today requires both measurement of their cardiac dose and dose-response relationships, which depend on cardiac dosimetry of past regimens, in conjunction with long-term follow-up data. Methods: Virtual simulation and computed tomography 3-dimensional treatment planning on a representative patient were used to estimate mean heart and coronary artery doses for women irradiated since 1950 in 71 randomised trials in the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) overview. Patient-to-patient variability in cardiac dose was assessed. Heart and coronary artery doses were also calculated for breast cancer radiotherapy regimens used since the 1950s in Sweden. Cardiac doses from contemporary (year 2006) radiotherapy were assessed for 55 patients who received tangential breast cancer irradiation at a large UK radiotherapy centre. The maximum heart distance (i.e. the maximum distance between the anterior cardiac contour and the posterior tangential field edges) was measured for the left-sided patients, and its value as a predictor of cardiac doses assessed. Results: Mean heart dose for women irradiated in the EBCTCG trials varied from <1 to 18 Gray, and mean coronary artery dose from <1 to 57 Gray. Patient-to-patient variability was moderate. Mean heart dose for women irradiated in Sweden since the 1950s varied from <1 to 24 Gray, and mean coronary artery dose from <1 to 46 Gray. Heart dose from tangential irradiation has reduced over the past four decades. However, mean heart dose for left-sided patients irradiated in 2006 was 2 Gray and around half of them still received >20 Gray to parts of the heart and left anterior descending coronary artery. For these patients, maximum heart distance was a reliable predictor of cardiac doses. For the other patients, mean heart dose varied little and was usually less than 2 Gray. Conclusions: Cardiac doses from breast cancer radiotherapy can be estimated reliably and are now available for use in deriving dose-response relationships in the EBCTCG data and in a Scandinavian case-control study. Cardiac dose has reduced over the past four decades. Therefore the cardiac risk is also likely to have reduced. Nevertheless, for some patients, parts of the heart still receive >20 Gray in the year 2006.
APA, Harvard, Vancouver, ISO, and other styles
3

Hall, Emma. "Benign breast disease as a risk factor for breast cancer." Thesis, University College London (University of London), 1999. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.322197.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Huguet, Emmanuel L. "Wnt genes in human breast biology." Thesis, University of Oxford, 1995. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.297228.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Bird, Katherine. "Dysregulation of the polycystic kidney disease pathway in breast cancer." Thesis, University of Cambridge, 2014. https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.708059.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Qianren, Jin. "Search for susceptibility loci and candidate genes for breast cancer /." Stockholm, 2004. http://diss.kib.ki.se/2004/91-7140-030-3/.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Wedrén, Sara. "Genetic susceptibility to breast and endometrial cancer /." Stockholm, 2004. http://diss.kib.ki.se/2004/91-7140-053-2/.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Bundred, Nigel James. "The objective identification of apocrine change in benign and malignant breast disease." Thesis, University of Newcastle Upon Tyne, 1989. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.241376.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Erbas, Hakan. "Effect of breast cyst fluid and its constituents on oestrogen metabolism in breast cancer cell lines." Thesis, University of Newcastle Upon Tyne, 1999. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.265481.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Søndergaard, Karen Lynn. "A study of hypoxia inducible factor and related genes in disease in man." Thesis, University of Plymouth, 2002. http://hdl.handle.net/10026.1/2496.

Full text
Abstract:
In this study, the mRNA and protein levels of hypoxia inducible factor 1 (HIF-1α), and a number of genes regulated by hypoxia (VEGF, GLUT-1, p53), were determined in four breast carcinoma cell lines, peripheral blood mononuclear cells (PBMCs) of patients with breast cancer and Type 1 diabetes (TIDM), and in human breast and brain tumour tissue. Breast carcinoma cells and PMBCs from both patients and normal controls were exposed to hypoxia (≤1% 0 2) and/or high glucose. Both up-regulated and down-regulated HIF-1α, GLUT-1 and p53 mRNA expression was observed in the breast carcinoma cell lines exposed to hypoxia and/or high glucose, and in controls for osmolarity, confirming that hypoxic regulation of HIF-1α, p53 and possibly GLUT-1 occurs post-transcriptionally. Conversely, up-regulation of HIF- 1α and GLUT-1 mRNA was observed in patients with TIDM exposed to high glucose. The GLUT-1 mRNA up-regulation observed in patients without complications differed significantly from normal controls, where up to a 2 fold increase in expression was observed over that of patients with complications. This may indicate that the expression and function of glucose transporters differs in these patients, potentially leading to fewer complications. Investigation of breast and glial cell tumour tissue demonstrated that both HIF-1α and GLUT- 1 mRNA expression levels increase with disease progression, indicating that up-regulation of HIF-1α is partly at the transcriptional level (Søndergaard et al, 2002). Follow-up survival studies in all patients with glial cell tumours showed that HIF-1α protein expression is a significant prognostic factor in cumulative overall survival. An additional investigation of p53 or p73 polymorphisms in the development of carcinoma of the breast did not find that they were significant risk factors in the development of the disease in the British Caucasoid population. Further studies are required using larger sample populations investigating HIF-1α protein to determine the precise role of HIF-1 in the response to hypoxia and angiogenesis in disease in man.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Breast disease; Cancer"

1

Tkaczuk, Katherine H. R., Susan B. Kesmodel, and Steven J. Feigenberg, eds. Handbook of Breast Cancer and Related Breast Disease. New York, NY: Springer Publishing Company, 2016. http://dx.doi.org/10.1891/9781617052767.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Kahán, Zsuzsanna, ed. Breast Cancer, a Heterogeneous Disease Entity. Dordrecht: Springer Netherlands, 2011. http://dx.doi.org/10.1007/978-94-007-0489-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Atlas of breast disease. Philadelphia: B.C. Decker, 1991.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Kneece, Judy C. Breast cancer treatment handbook: Understanding the disease, treatments, emotions and recovery from breast cancer. 8th ed. North Charleston, SC: EduCare, 2012.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Kneece, Judy C. Breast cancer treatment handbook: Understanding the disease, treatments, emotions and recovery from breast cancer. 7th ed. North Charleston, SC: EduCare, 2009.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Piñeiro, Roberto, ed. Circulating Tumor Cells in Breast Cancer Metastatic Disease. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-35805-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Russo, Jose. Environment and breast cancer. New York: Springer, 2011.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

1952-, Gordon Barbara L., ed. Breast cancer recurrence and advanced disease: Comprehensive expert guidance. Durham [NC]: Duke University Press, 2010.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

International Symposium on Benign Breast Disease (6th 1995 London, England). Recent developments in the study of benign breast disease: Proceedings of the 6th International Symposium on Benign Breast Disease, London. New York: Parthenon Pub. Group, 1997.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

International Benign Breast Symposium (6th 1995 London, England). Recent developments in the study of benign breast disease: The proceedings of the 6th International Symposium on Benign Breast Disease, London. New York: Parthenon Pub. Group, 1997.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Breast disease; Cancer"

1

Kupres, Peggy. "Cancer Survivorship." In Breast Disease, 523–31. New York, NY: Springer New York, 2014. http://dx.doi.org/10.1007/978-1-4939-1145-5_33.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

McGuire, Kandace P. "Breast Cancer in Young Women (Premenopausal Breast Cancer)." In Breast Disease, 375–87. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-26012-9_22.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Alvarez, Ricardo Hugo, Shaheenah Dawood, and Massimo Cristofanilli. "Inflammatory Breast Cancer." In Breast Disease, 223–35. New York, NY: Springer New York, 2014. http://dx.doi.org/10.1007/978-1-4939-1145-5_15.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Igci, Abdullah, Mustafa Tukenmez, and Enver Özkurt. "Male Breast Cancer." In Breast Disease, 337–48. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-16792-9_22.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Cabioğlu, Neslihan, Ekrem Yavuz, and Adnan Aydiner. "Breast Cancer Staging." In Breast Disease, 25–51. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-16792-9_3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

İğci, Abdullah, Mustafa Tükenmez, and Enver Özkurt. "Male Breast Cancer." In Breast Disease, 389–403. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-26012-9_23.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Brockhausen, Inka, and William Kuhns. "Breast Cancer." In Glycoproteins and Human Disease, 209–15. Berlin, Heidelberg: Springer Berlin Heidelberg, 1997. http://dx.doi.org/10.1007/978-3-662-21960-7_24.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Tuzlali, Sitki. "Pathology of Breast Cancer." In Breast Disease, 201–20. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-04606-4_14.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Ismail-Khan, Roohi, Susan Minton, and Nazanin Khakpour. "Triple-Negative Breast Cancer." In Breast Disease, 463–72. New York, NY: Springer New York, 2014. http://dx.doi.org/10.1007/978-1-4939-1145-5_29.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Costa, Maurício Magalhães, and Paula Saldanha. "Breast Cancer in Pregnancy." In Breast Disease, 349–57. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-16792-9_23.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Breast disease; Cancer"

1

"Case series: Breast and ovarian cancer syndrome." In 16th Annual International Conference RGCON. Thieme Medical and Scientific Publishers Private Ltd., 2016. http://dx.doi.org/10.1055/s-0039-1685364.

Full text
Abstract:
Aims and Objectives: To report a series of cases with breast and ovarian carcinomas either in same patient or in a family and identifying the importance of BRCA 1, 2 genetic testing in such individuals. Materials and Methods: The medical records of breast and ovarian cancer patients operated over past 3 years at a single institute were reviewed retrospectively and their clinical profile, family history, final pathological reports and follow up data was collected. Results: 8 patients were found to have breast and ovarian malignancies, out of which 3 had synchronous breast and ovarian cancers, 4 had metachronous and 1 patient with ovarian cancer had history of breast cancer in family. Median age of presentation to the hospital was 47 years and median time interval in metachronous disease patients was 5.5 years. Conclusion: About 5% of people who have breast cancer and about 10% of women who have ovarian cancer have HBOC, caused by germline mutation in BRCA 1, 2 gene. These individuals have increased risk of developing breast cancer at younger age, TNBC, or developing a second primary in breast or ovary plus an overall risk of breast/ovarian/prostate/pancreatic malignancies in other family members due to inheritable mutation. Identification of BRCA mutation in such individuals can help family members to undergo genetic counseling and follow different screening and prevention guidelines from general population thus reducing the cancer risks.
APA, Harvard, Vancouver, ISO, and other styles
2

"Case series: Breast and ovarian cancer syndrome." In 16th Annual International Conference RGCON. Thieme Medical and Scientific Publishers Private Ltd., 2016. http://dx.doi.org/10.1055/s-0039-1685348.

Full text
Abstract:
Aims and Objectives: To report a series of cases with breast and ovarian carcinomas either in same patient or in a family and identifying the importance of BRCA 1,2 genetic testing in such individuals. Materials and Methods: The medical records of breast and ovarian cancer patients operated over past 3 years at a single institute were reviewed retrospectively and their clinical profile, family history, final pathological reports and follow up data was collected. Results: 8 patients were found to have breast and ovarian malignancies, out of which 3 had synchronous breast and ovarian cancers, 4 had metachronous and 1 patient with ovarian cancer had history of breast cancer in family. Median age of presentation to the hospital was 47 years and median time interval in metachronous disease patients was 5.5 years. Conclusion: About 5% of people who have breast cancer and about 10% of women who have ovarian cancer have HBOC, caused by germline mutation in BRCA1, 2 gene. These individuals have increased risk of developing breast cancer at younger age, TNBC, or developing a second primary in breast or ovary plus an overall risk of breast/ovarian/prostate/pancreatic malignancies in other family members due to inheritable mutation. Identification of BRCA mutation in such individuals can help family members to undergo genetic counseling and follow different screening and prevention guidelines from general population thus reducing the cancer risks.
APA, Harvard, Vancouver, ISO, and other styles
3

Carrijo, Sarah B. D., Lucas F. S. Pereira, Larissa F. Almeida, Jordana M. Oliveira, Cesar A. S. T. Vilanova Costa, and Antonio M. T. C. Silva. "UNILATERAL PAGET’S DISEASE IN YOUNG ADULT: A CASE REPORT." In Brazilian Breast Cancer Symposium. v29s1, 2019. http://dx.doi.org/10.29289/259453942019v29s1ep54.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Stearns, V. "ES1-3: Treatment of Metastatic Breast Cancer – Breast Cancer as a Chronic Disease: Triple Negative Breast Cancer." In Abstracts: Thirty-Fourth Annual CTRC‐AACR San Antonio Breast Cancer Symposium‐‐ Dec 6‐10, 2011; San Antonio, TX. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/0008-5472.sabcs11-es1-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Da Silva, Andrio Rodrigo Corrêa, Iális Cavalcante de Paula Júnior, and Márcio André Baima Amora. "Breast cancer detection in histopathological images using convolutional neural networks." In Anais do Simpósio Brasileiro de Computação Aplicada à Saúde. Sociedade Brasileira de Computação - SBC, 2019. http://dx.doi.org/10.5753/sbcas.2019.6237.

Full text
Abstract:
Breast cancer is one of the biggest causes of death among women around the world. Diagnosing this disease early can offer better treatment to the patient. Intelligent systems have been used for the detection of diseases using images. In this work a convolutional neural network was used for the detection of breast cancer in histopathological images through Keras library and TensorFlow framework. Models were created for 4 datasets with different magnifying factors (40x, 100x, 200x and 400x). Using k-fold cross-validation, it was found that there was a better result for the set of 400x images with 98.44% accuracy in the training data. The set of 200x images obtained a better result for recall and f1-score.
APA, Harvard, Vancouver, ISO, and other styles
6

Ghosh, K., VS Pankratz, CA Reynolds, RA Vierkant, SS Anderson, AC Degnim, DW Visscher, MH Frost, CM Vachon, and LC Hartmann. "Benign breast disease and breast cancer risk in young women." In CTRC-AACR San Antonio Breast Cancer Symposium: 2008 Abstracts. American Association for Cancer Research, 2009. http://dx.doi.org/10.1158/0008-5472.sabcs-62.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Stokol, Tracy, Mandy B. Esch, Nozomi Nishimura, Chris Schaffer, Janelle L. Daddona, David J. Post, and Dhruv P. Desai. "Little Channels, Big Disease: Using Microfluidics to Investigate Cancer Metastasis." In ASME 2011 9th International Conference on Nanochannels, Microchannels, and Minichannels. ASMEDC, 2011. http://dx.doi.org/10.1115/icnmm2011-58298.

Full text
Abstract:
The leading cause of death in human patients with malignant cancer is the dissemination of the primary tumor to secondary sites throughout the body. It is well known that cancers metastasize to certain tissues (e.g. breast cancer typically spreads to the lungs. brain and bone), in a pattern that cannot be explained by blood flow from the primary tumor or simple mechanical arrest. Circulating tumor cells usually arrest in the microvasculature of target tissues. At these sites, they must adhere to the endothelium, survive, proliferate and extravasate in order to form a secondary tumor. In vitro tools that appropriately mimic the microvasculature in which cancer metastasis occurs have been largely unavailable. With the advent of microfluidic and nanotechnology, we can now more accurately model the complexity of the microvascular environment, in terms of representative endothelial cells, geometry, shear stress and exposure to organ-specific environmental cues. This talk will focus on the use of microfluidic devices to explore mechanisms involved in tumor-endothelial cell interactions that govern cancer metastasis to organ specific sites.
APA, Harvard, Vancouver, ISO, and other styles
8

Nguyen, Thanh-Tam, Thanh-Hai Nguyen, Ba-Viet Ngo, and Duc-Dung Vo. "Breast Image Segmentation for evaluation of Cancer Disease." In 2020 5th International Conference on Green Technology and Sustainable Development (GTSD). IEEE, 2020. http://dx.doi.org/10.1109/gtsd50082.2020.9303133.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

McArdle, K., S. Shokuhi, Y. Chan, L. Vishwanath, and H. Brown. "Are there preoperative predictors for invasive disease in DCIS?." In CTRC-AACR San Antonio Breast Cancer Symposium: 2008 Abstracts. American Association for Cancer Research, 2009. http://dx.doi.org/10.1158/0008-5472.sabcs-3014.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Kurniasari, Lia, Aji Mohammad Irfannur, Ayu Mardiana, Elvi Natalia, Erlinda Rara Sulviana, and Nur Ainun Jariah. "Predisposing and Reinforcing Factors in Patients with Breast Cancer in Samarinda, East Kalimantan." In The 7th International Conference on Public Health 2020. Masters Program in Public Health, Universitas Sebelas Maret, 2020. http://dx.doi.org/10.26911/the7thicph.01.32.

Full text
Abstract:
ABSTRACT Background: Breast Cancer can be disturbed for health and psychologically. Breast cancer has reached the second deadly disease. Causative factors include age, marital status, use of hormonal contraception, history of breastfeeding, family history, family support, self-acceptance, stress levels and knowledge of breast self-exam. This study aimed to investigate the factors predisposing and reinforcing the incidence of breast cancer in Samarinda, East Kalimantan. Subject and Method: This was a cross sectional study conducted in Samarinda, East Kalimantan. A total of 216 samples by using accidental sampling were selected for this study. The dependent variable was incidence of breast cancer. The independent variables were education, marital status, use of hormonal contraception, history of breastfeeding, family history, family support, self-acceptance, stress levels and knowledge of breast self-exam. The data were collected by questionnaire via google form. Data analysis used Chi Square test. Results: The significant risk factors of breast cancer were education, marital status, hormonal contraception, history of breastfeeding, stress conditions, and self-acceptance. family history and family support, and breast self-exam knowledge were insignificantly associate with the risk of breast cancer. Conclusion: The significant risk factors of breast cancer are education, marital status, hormonal contraception, history of breastfeeding, stress conditions, and self-acceptance. Family history and family support, and breast self-exam knowledge are insignificantly associate with the risk of breast cancer. Keywords: Breast cancer, predisposing, reinforcing. Correspondence: Lia Kurniasari. Public Health Study Program, Faculty of Health and Pharmacy, Muhammadiyah University of East Kalimantan, Indonesia. Email: liakesmas@umkt.ac.id. Mobile: +6285231669773. DOI: https://doi.org/10.26911/the7thicph.01.32
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Breast disease; Cancer"

1

Hartmann, Lynn C. Benign Breast Disease: Toward Molecular Prediction of Breast Cancer Risk. Fort Belvoir, VA: Defense Technical Information Center, June 2005. http://dx.doi.org/10.21236/ada442889.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Hartmann, Lynn C. Benign Breast Disease: Toward Molecular Prediction of Breast Cancer Risk. Fort Belvoir, VA: Defense Technical Information Center, June 2004. http://dx.doi.org/10.21236/ada427975.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Hartmann, Lynn C. Benign Breast Disease: Toward Molecular Prediction of Breast Cancer Risk. Fort Belvoir, VA: Defense Technical Information Center, June 2003. http://dx.doi.org/10.21236/ada418667.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Hartmann, Lynn C. Benign Breast Disease: Toward Molecular Prediction of Breast Cancer Risk. Fort Belvoir, VA: Defense Technical Information Center, June 2009. http://dx.doi.org/10.21236/ada552165.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Mandelson, Margaret. Markers of Breast Cancer Risk in Women With Benign Breast Disease. Fort Belvoir, VA: Defense Technical Information Center, October 2002. http://dx.doi.org/10.21236/ada412798.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Robison, Leslie. Breast Cancer Following Pediatric Hodgkins Disease: Risk Factors and Intervention. Fort Belvoir, VA: Defense Technical Information Center, July 1999. http://dx.doi.org/10.21236/ada374757.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Robinson, Leslie L. Breast Cancer Following Pediatric Hodgkin's Disease: Risk Factors and Intervention. Fort Belvoir, VA: Defense Technical Information Center, July 2000. http://dx.doi.org/10.21236/ada383953.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Wells, Robert. Role of Melatonin in the Prevention of Breast Cancer in Patients with Cystic Breast Disease. Fort Belvoir, VA: Defense Technical Information Center, September 2001. http://dx.doi.org/10.21236/ada403645.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Wells, Robert L. Role of Melatonin in the Prevention of Breast Cancer in Patients With Cystic Breast Disease. Fort Belvoir, VA: Defense Technical Information Center, September 2003. http://dx.doi.org/10.21236/ada424033.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Wells, Robert L. Role of Melatonin in the Prevention of Breast Cancer in Patients With Cystic Breast Disease. Fort Belvoir, VA: Defense Technical Information Center, September 2000. http://dx.doi.org/10.21236/ada392483.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Breast disease; Cancer' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography